FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40560 ProKidney Corp. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of incorporation or org ...

Index UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 11-3234779 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commiss ...

Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update CAMBRIDGE, Mass., Aug 12, 2025 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. "During the second quarter, we announced that th ...

收入和利润（同比环比） - 2025财年第二季度总收入为370万美元，同比下降10.0%，环比下降14.8%[4] - 新产品收入为290万美元，同比下降3.6%，环比下降22.1%[5] - 成熟产品收入为80万美元，低于2024年第二季度的110万美元，但高于2025年第一季度的60万美元[5] - GAAP净亏损为270万美元，每股亏损0.17美元，同比扩大110万美元[8] - 非GAAP净亏损为150万美元，每股亏损0.09美元，同比扩大80万美元[9] - 2025年第二季度GAAP运营亏损为2,522千美元，较2024年同期的1,200千美元亏损扩大110.2%[26] - 2025年上半年GAAP净亏损从2024年同期的1,156千美元扩大至4,751千美元，增幅达311%[26] - 2025年第二季度非GAAP运营亏损为1,358千美元，较GAAP亏损收窄46.2%[26] - 2025年上半年非GAAP每股亏损为0.17美元，较GAAP每股亏损0.30美元改善43.3%[26] - Non-GAAP净亏损为每股0.09美元[27] 成本和费用（同比环比） - GAAP毛利率为25.9%，同比下降28.8个百分点，环比下降17.5个百分点[6] - 非GAAP毛利率为31.0%，同比下降27.2个百分点，环比下降16.1个百分点[6] - GAAP运营费用为350万美元，同比增加10万美元，环比减少40万美元[7] - 非GAAP运营费用为250万美元，同比减少30万美元，环比减少50万美元[7] - 股票薪酬费用在2025年第二季度总计843千美元，占运营费用的33.4%[26] - 股票薪酬补偿占收入成本的比例为5.1%[27] - 公司2025年第二季度重组成本为21千美元，上半年累计75千美元[26] 各条业务线表现 - 新产品收入占比79%，成熟产品收入占比21%[29] - 新产品收入占比环比下降4%[29] - 成熟产品收入占比环比上升33%[29] - 公司加速推出Australis 2.0 IP生成工具，计划在第四季度部署[3] 各地区表现 - 亚太地区收入占比17%，同比增长57%[29] - 北美地区收入占比80%，同比下降18%[29] - 欧洲地区收入占比3%，同比下降6%[29] 其他财务数据 - 公司总资产从2024年12月的51,933千美元下降至2025年6月的50,214千美元，下降幅度为3.3%[24] - 现金及现金等价物从2024年12月的21,859千美元减少至2025年6月的19,191千美元，下降12.2%[24] - 应收账款从2024年12月的2,426千美元大幅下降至2025年6月的974千美元，降幅达59.9%[24] - 公司流动负债从2024年12月的25,397千美元降至2025年6月的21,525千美元，减少15.2%[24] - US GAAP毛利率从持续经营业务为25.9%[27] - Non-GAAP毛利率从持续经营业务为31.0%[27]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5696597 (Stat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________ Form 10-Q ______________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR Delaware 47-4515206 (State or other jurisdiction of incorporation or organization) 1150 Veterans Boulevard South San Francisco, CA 94080 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) (925) 407-1049 (Registrant's telephone number, including ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from ________________ to __________________ Commission File Number: 001-36291 (State or other jurisdiction of incorporation or organization) Not Applicable (I.R.S ...

Exhibit 99.1 Iridex Reports Second Quarter 2025 Financial Results MOUNTAIN VIEW, Calif., August 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Financial Highlights "Our second quarter results represent the transformational p ...

NEWS RELEASE LUMENTUM ANNOUNCES FOURTH QUARTER AND FULL FISCAL YEAR 2025 RESULTS Fiscal Fourth Quarter Highlights: Fiscal Year 2025 Highlights: San Jose, Calif., August 12, 2025 – Lumentum Holdings Inc. ("Lumentum" or the "Company") today reported results for its fourth quarter and full fiscal year ended June 28, 2025. "In our fiscal fourth quarter, we executed exceptionally well in meeting robust demand across our portfolio of cloud products supporting AI data centers," said Michael Hurlston, Lumentum Pres ...